The first reported function blocking anti-GPVI antibody (JAQ1) was raised against mouse GPVI.40In vivo administration of JAQ1 IgG in mice induces GPVI immunodepletion, resulting in long-term protection in a range of disease models, such as arterial thrombosis,11 ischaemic stroke,6–8 myocardial I/R injury,13 and LPS-induced lung injury10 while only moderately affecting tail bleeding time.11 Similar mechanisms of GPVI depletion also exist in humans,14,41 but persistent GPVI inhibition may not be desired in clinical settings. The gene discussed is GP6; the disease is Arterial thrombosis.